The physiological barriers of the eye pose challenges to the delivery of the array of
therapeutics for ocular diseases. Hydrogels have been widely explored for medical …

Although once daily anti-glaucoma drug therapy is a current clinical reality, most therapies
require multiple dosing and there is an unmet need to develop convenient, safe, and …

A number of pharmacological targets are exploited to modify the parameters in the
Goldmann equation and reduce the intraocular pressure (IOP). This strategy constitutes the …

Glaucoma is a leading cause of irreversible visual impairment and blindness, affecting over
76.0 million people worldwide in 2020, with a predicted increase to 111.8 million by 2040 …

Introduction: Nonadherence to medication is a challenge to effective treatment of many
chronic diseases, including glaucoma, and persists even with interventions aimed at …

Microinvasive glaucoma surgery (MIGS) is a potentially safer and more efficacious method
studied in patients with mild-to-moderate open-angle glaucoma requiring less invasive …

Normally, trabecular meshwork (TM) and Schlemm's canal inner wall endothelial cells within
the aqueous humor outflow pathway maintain intraocular pressure within a narrow safe …

New technologies for delivery of drugs, such as small molecules and biologics, are of
growing interest among clinical and pharmaceutical researchers for use in treating anterior …

Diabetic retinopathy (DR) is a multifactorial progressive disease of the retina and a leading
cause of vision loss. DR has long been regarded as a vascular disorder, although neuronal …

Objectives: Identify risk factors and early signs of open-angle glaucoma during routine
patient evaluations. Differentiate between open-angle glaucoma and other ocular conditions …